It was great to be back at the Department of Anthropology, History and Social Medicine at UCSF for a few days last week. During my visit I gave a talk as part of the Culpeper Seminar Series on ethics of CRISPR genome editing technologies. I was also interviewed by Professor Brian Dolan, Director of UC Medical Humanities Press and Professor of Social Medicine at UCSF, about my book “From Bench to Bedside, to Track and Field: The Context of Enhancement and its Ethical Relevance” published for UC Medical Humanities Press.
In the podcast (available here) I discuss genome editing technologies to alter the human embryo and to select children’s traits, genetic technologies to enhance athletic performance, and doping in professional sport.
The podcast is available here:
I am very pleased to announce that my PhD thesis is forthcoming for the UC Perspectives in Medical Humanities Book Series, with title “From bench, to bedside, to track & Field: the context of enhancement and its ethical relevance“, and with a foreword by Professor Søren Holm of Manchester University. The series publishes scholarship produced or reviewed under the auspices of the University of California Medical Humanities Consortium, a multi-campus collaborative of faculty, students and trainees in the humanities, medicine, and health sciences.The editor of the series is Professor Brian Dolan.
From the back cover:
What is it to talk about gene transfer, gene therapy, and gene doping? Is choosing deafness with preimplantation genetic diagnosis an ethical way to carry on a cultural bloodline? What are the ethical and social implications of genetic testing to identify precocious talents? Should sponsors be held responsible for the doping behaviours of their athletes?These are only some of the questions that Dr. Silvia Camporesi addresses in this book, through a contextual, bottom up approach based on real-world ethical dilemmas. This book represents a unique contribution to the debate on enhancement technologies as it spans from the bench of molecular biology where the technologies are being developed, to the bedside of a clinical trial where they are used for selective reproduction or for first-in-human gene therapy studies, to the track & field where they are being applied to enhance human athletic performance. These investigations address current debates regarding the resurgence of eugenics in relation to genetic technologies, and provide a clear and much needed ethical autopsy of contemporary genetic practices.
Paperback | 978-0-9889865-4-1 | October 2014 | pp 185 | $24.95
Many thanks to Brad Partridge, NHMRC Research Fellow in Public Health based at the University of Queensland, UQ Centre for Clinical Research, for his nice comments to my article with Mike McNamee on guinea pigs in elite sport. You can read below an excerpt of the comment.
[…] In an article published in Philosophy, Ethics, and Humanities in Medicine, British bioethicist Silvia Camporesi and philosopher Michael McNamee argue that many athletes are essentially vulnerable research subjects and the growing translation of innovations directly into athletic environments for performance enhancement amounts to unregulated clinical research. […] Camporesi and McNamee suggest the need for a framework to establish claims about performance enhancement and risks to health. Perhaps greater transparency and visibility will encourage more compliance with the WADA Code and reduce the incentive to treat athletes as guinea pigs. This system could also serve to justify the inclusion of substances and methods on the WADA Prohibited List.”
If interested in reading more, see here on MJA Insight.